^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
JNJ-8343
i
Other names: JNJ-8343, JNJ-78278343
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
J&J, Zymeworks
Drug class:
CD3 agonist, KLK2 inhibitor
Related drugs:
5ms
A Study of JNJ-78278343 in Combination With JNJ-63723283 (Cetrelimab) for Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov)
P1, N=20, Recruiting, Janssen Research & Development, LLC | Phase classification: P1b --> P1
Phase classification • Combination therapy • Metastases
|
cetrelimab (JNJ-63723283) • JNJ-8343
6ms
A Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer (clinicaltrials.gov)
P1, N=165, Recruiting, Janssen Research & Development, LLC | Trial completion date: Nov 2024 --> Nov 2025
Trial completion date • Metastases
|
JNJ-8343
6ms
A Study of JNJ-87189401 Plus JNJ-78278343 for Advanced Prostate Cancer (clinicaltrials.gov)
P1, N=110, Recruiting, Janssen Research & Development, LLC | Not yet recruiting --> Recruiting
Enrollment open • Metastases
|
JNJ-8343
7ms
A Study of JNJ-87189401 Plus JNJ-78278343 for Advanced Prostate Cancer (clinicaltrials.gov)
P1, N=110, Not yet recruiting, Janssen Research & Development, LLC
New P1 trial • Metastases
|
JNJ-8343
1year
A Study of JNJ-78278343 in Combination With JNJ-63723283 (Cetrelimab) for Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov)
P1b, N=20, Recruiting, Janssen Research & Development, LLC | Not yet recruiting --> Recruiting | N=40 --> 20
Enrollment open • Enrollment change
|
cetrelimab (JNJ-63723283) • JNJ-8343
Share via
